Company Dossier · Health Care
Henry Schein
- S&P 500
- Russell 1000
What Henry Schein is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 27, 2026: $13.6 billion, up 6.5% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 27, 2026: $0.57 billion, up 50% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 27, 2026: $0.13 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 27, 2025: $0.85 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 27, 2025: $0.49 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 24, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q2 2026: $0.7 million on the open market.SEC Form 4
- 570 institutional managers reported a position at June 30, 2026 (+5 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 2.U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Henry Schein is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Confident
Expanding ↔ Retrenching
Retrenching
- Capital spending40th pct
- Debt raised43rd pct
- Buybacks vs capex19th pct
- Hiring filings31st pct
- Deals and private raises49th pct
- Patent publications12th pct
Confident ↔ Hedging
Confident
- Call sentiment82nd pct
- Call confidence65th pct
- Guidance changes63rd pct
- Risk factors added79th pct
- Insider open-market trades91st pct
- + Call sentiment
- + Insider open-market trades
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver28th pct
- Stress filings46th pct
Credit
How these are built →Henry Schein's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$3.5B
- Due within a year $1.2B
- Longer term $2.3B
- Default point $2.3B (short + ½ long)
Finance leases included · Jun 27, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Henry Schein, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralHenry Schein announces CFO role transition (HSIC:NASDAQ)
seekingalpha.com · via Marketaux · Oct 8, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)third_quarter 2026 · $0.1 million
- Oct 8, 20268-KDirector or officer changeItem 5.02
- Sep 22, 20268-KMaterial agreement signedItem 1.01
- Jul 30, 20268-KDirector or officer changeItem 5.02
- Jul 17, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)second_quarter 2026 · $0.0 million
- Jul 17, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)second_quarter 2026 · $0.1 million
- May 22, 20268-KShareholder vote resultsItem 5.07
- Apr 17, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)first_quarter 2026 · $0.1 million
- Apr 17, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)first_quarter 2026 · $0.0 million
- Feb 24, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 24, 2026Patent
- Jan 21, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)fourth_quarter 2025 · $0.0 million
- Jan 16, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)fourth_quarter 2025 · $0.1 million
- Jan 12, 20268-KDirector or officer changeItem 5.02
- Dec 30, 2025Patent
- Dec 23, 20258-KMaterial agreement signedItem 1.01
- Dec 23, 20258-KDirector or officer changeItem 5.02
- Dec 9, 20258-KMaterial agreement signedItem 1.01
- Oct 21, 2025LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)third_quarter 2025 · $0.0 million
- Sep 9, 20258-KDirector or officer changeItem 5.02
- Jul 15, 20258-KDirector or officer changeItem 5.02
- Jun 9, 20258-KMaterial agreement signedItem 1.01
- May 23, 20258-KShareholder vote resultsItem 5.07
- May 16, 20258-KMaterial agreement signedItem 1.01
- May 16, 20258-KDirector or officer changeItem 5.02
- May 2, 20258-KMaterial agreement signedItem 1.01
- May 2, 20258-KDirector or officer changeItem 5.02
- Apr 15, 20258-KDirector or officer changeItem 5.02
- Apr 9, 20258-KMaterial agreement signedItem 1.01
- Mar 14, 20258-KDirector or officer changeItem 5.02
- Feb 25, 202510-KAnnual report (10-K)5 risk factors added, 1 removed
- Jan 29, 20258-KDirector or officer changeItem 5.02
- Jan 29, 20258-KMaterial agreement signedItem 1.01
- Oct 29, 2024Patent
- Jul 9, 2024Patent
- Feb 28, 202410-K
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |
| McKesson Corporation MCK | $411B | $6.4B | Jun 30, 2026 |
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| BrightSpring Health Services BTSG | $14.4B | $0.4B | Jun 30, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |
| Vertex Pharmaceuticals VRTX | $12.6B | $3.8B | Jun 30, 2026 |